Clinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH
Clinical and Applied Thrombosis/Hemostasis · 2026
DOI: 10.1177/10760296251405423 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, 2026. Verfasst von Seung Ki Min und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea. Hauptthemen laut MEDLINE: Hemostatics, Gastrectomy. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
Hemogram is a novel biodegradable powdered hemostatic agent developed by binding calcium ions (Ca² + ) to carboxymethyl starch (CM-starch) and applying granulation technology to enhance blood absorption and hemostatic efficacy. This study aimed to evaluate the clinical efficacy and safety of Hemogram compared with the commercially available agent Arista™ AH in patients undergoing gastrectomy.
Methods
This randomized controlled trial was conducted at Samsung Medical Center and included patients who experienced intraoperative oozing-type bleeding during gastrectomy. A total of 64 patients were enrolled and evenly randomized to receive either Hemogram (n = 32) or Arista™ AH (n = 32) for local hemostasis. The primary efficacy endpoint was the hemostatic success rate within 5 min. Secondary endpoints included hemostasis time, re-bleeding rate, number of hemostatic agent units used, transfusion volume, length of hospital stay, and incidence of adverse events.
Results
Hemostatic success within 5 min was achieved in 100% (32/32) of the Hemogram group and 96.9% (31/32) of the Arista™ AH group, with no statistically significant difference between the two (P > 0.05). The mean time to hemostasis was 1.25 ± 0.80 min in the Hemogram group and 1.52 ± 0.85 min in the Arista™ AH group. No re-bleeding events were observed in the Hemogram group, while one case of re-bleeding (3.3%) was reported in the Arista™ AH group. There were no significant differences between groups in terms of transfusion volume, length of hospitalization, or adverse event rates.
Conclusion
Hemogram demonstrated non-inferior hemostatic efficacy and safety compared to Arista™ AH in patients undergoing gastrectomy. These findings suggest that Hemogram is a promising and clinically applicable hemostatic agent for surgical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea.
- Theracion Biomedical Co., Ltd, Seongnam, Gyeonggi 13207, South Korea.
ORCID-Profile: Seung Ki Min
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
Zitieren
APA
Min, S. K., Oh, S. E., An, J. Y., Kim, H. K., Kim, E. J., & Choi, M. G. (2026). Clinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296251405423
Vancouver
Min SK, Oh SE, An JY, Kim HK, Kim EJ, Choi MG. Clinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH. Clinical and Applied Thrombosis/Hemostasis. 2026. doi:10.1177/10760296251405423
BibTeX
@article{Min2026,
author = {Min, Seung Ki and Oh, Sung Eun and An, Ji Yeong and Kim, Hyun Kyoon and Kim, Eun Jin and Choi, Min-Gew},
title = {Clinical Evaluation of the Hemostatic Efficacy and Safety of a Biodegradable Hemostatic Agent, Hemogram: A Comparative Study with Arista™ AH},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
doi = {10.1177/10760296251405423}
}
EUVIMED